BackgroundThe rapid spread of HBV has resulted in the emergence of new variants. These viral genotypes and variants, in addition to carcinogenic risk, can be key predictors of therapy response and out
Wa (G1P[8]), DS-1 (G2P[4]), and AU-1(G3P[9]) strains were used as references for genotype 1 (Wa-like), genotype 2 (DS-1 like), and genotype 3 (AU-1 like), respectively.
a. Year of strain isolation or deposition into the STEC Reference Center at Michigan State University. b. Unknown refers to missing data; HUS, hemolytic uremic syndrome.
